Manage Account - ModernMedicine

Off-label bevacizumab shows promise for treating AMD
Publish date: February 1, 2006
By: Lynda Charters
Source:

Chicago—Off-label use of intravitreal bevacizumab (Avastin, Genentech) now holds promise for the treatment of neovascular age-related macular degeneration (AMD).

The journal page you requested is now available only to registered Modern Medicine members.

Register Here

Registration is Free!
(and Takes Less than a Minute)

RegisterUS Physicians, click here
for express registration.

RegisterHealthcare Professionals,
click here

Modern Medicine Offers:
» Practice Management Advice
» CME / ICD-9 Coding / Formulary
» Patient Education Handouts
» Peer-reviewed Articles
» Conference Coverage, Email Alerts & More

Click Here to Watch the Tour

Already Registered?

Login Now

Login Email:Password:
Forgot Your Password?Remember me.
Source: Ophthalmology Times, 2/1/2006
Click here